Cost Effectiveness of a Shorter Moxifloxacin Based Regimen for Treating Drug Sensitive Tuberculosis in India.

Muniyandi, Malaisamy and Karikalan, Nagarajan and Velayutham, Banurekha and Rajsekar, Kavitha and Padmapriyadarsini, Chandrasekaran (2022) Cost Effectiveness of a Shorter Moxifloxacin Based Regimen for Treating Drug Sensitive Tuberculosis in India. Tropical medicine and infectious disease, 7 (10). ISSN 2414-6366

Archive 202207.pdf - Published Version Download (475kB)

Abstract

Globally efforts are underway to shorten the existing 6-month tuberculosis (TB) treatment regimen for drug-sensitive patients, which would be equally effective and safe. At present, there is a lack of evidence on the cost implications of a shorter 4-month TB regimen in India. This economic modeling study was conducted in the Indian context with a high TB burden. We used a hybrid economic model comprising of a decision tree and Markov analysis. The study estimated the incremental costs, life years (LYs), and quality-adjusted life years (QALYs) gained by the introduction of a Moxifloxacin-based shorter 4-month treatment regimen for pulmonary TB patients. The outcomes are expressed in incremental cost-effectiveness ratios (ICERs) per QALYs gained. The cost per case to be treated under the 4-month regimen was USD 145.94 whereas for the 6-month regimen it was USD 150.39. A shorter 4-month TB regimen was cost-saving with USD 4.62 per LY and USD 5.29 per QALY. One-way sensitivity analysis revealed that the cost of the drugs for the 4-month regimen, hospitalization cost for adverse drug reactions, and human resources incurred for the 6-month regimen had a higher influence on the ICER. The probability sensitivity analysis highlighted that the joint incremental cost and effectiveness using QALY were less costly and more effective for 67% of the iteration values. The cost-effectiveness acceptability curve highlights that the 4-month regimen was dominant to both patients and the National TB Elimination Programme in India as compared to the 6-month regimen at different cost-effectiveness threshold values.

Affiliation:	ICMR-National Institute for Research in Tuberculosis
Item Type:	Article
Uncontrolled Keywords:	tuberculosis; short course TB regimen; cost‐utility; life years gained; QALYs gained; shorter moxifloxacin‐based regimen
Subjects:	Tuberculosis > Economical Research
Divisions:	Health Economics
Depositing User:	Dr. Rathinasabapati R
Date Deposited:	29 Mar 2023 06:59
Last Modified:	29 Mar 2023 06:59
URI:	http://eprints.nirt.res.in/id/eprint/1891

Actions (login required)

View Item